Clinical Trials Logo

Clinical Trial Summary

Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children. Current WHO-recommended rifampicin dosages result in low concentrations in most children, and high-dose rifampicin may improve outcomes and shorten treatment duration. Yet the impact of high-dose rifampicin on dolutegravir exposures has not been examined in children. This study aims to evaluate the safety and pharmacokinetics of dolutegravir twice daily among HIV/TB coinfected children receiving standard-dose and high-dose rifampicin.

Clinical Trial Description

This study is a prospective, single-arm, open-label, intensive and sparse pharmacokinetic (PK) and safety study to evaluate steady-state dolutegravir (DTG) concentrations among 20 HIV/TB coinfected children 4 weeks to <6 years of age requiring concurrent TB treatment. Ten patients will be recruited into each of two age cohorts: 4 weeks to <2 years and ≥2 years to <6 years. Children will be recruited from two large pediatric HIV clinics in Nigeria. Children in this study will receive HIV/TB cotreatment that is considered standard of care consisting of DTG twice daily during rifampicin (RIF)-containing TB treatment. For this portion of the study, the primary intervention is additional blood sampling for drug concentration determination and biomarker assessment. Additionally, during a two week period (study weeks 20-21), the RIF dose will be increased from standard-dose to high-dose RIF, during which two-way PK and toxicity monitoring will occur. Clinical and laboratory monitoring for toxicity during HIV/TB cotreatment is consistent with routine care. PK sampling for drug concentration determination will occur at three time points during the 48-week study. Specifically, PK sampling will occur at week-20 to evaluate DTG twice daily during standard-dose RIF, week-22 to evaluate DTG twice daily during high-dose RIF, and at week-30 to evaluate DTG once daily after TB treatment is complete. Additionally, the endogenous biomarker of CYP3A4 activity, 4-beta-hydroxycholesterol to cholesterol ratio, will be evaluated to advance understanding of underlying mechanisms of drug action. Blood sampling to quantify this biomarker will occur at either 4 (among ART-experienced children) or 5 (ART-naive) time points during the 48-week study. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05069688
Study type Interventional
Source Brigham and Women's Hospital
Contact Holly Rawizza, MD, MPH
Phone 617-432-4686
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date January 1, 2022
Completion date March 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Recruiting NCT04545164 - Computer Aided Screening for Tuberculosis in Low Resource Environments N/A
Not yet recruiting NCT04453293 - Immunization With BCG Vaccine to Prevent Tuberculosis Infection Phase 3
Enrolling by invitation NCT04988984 - Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Recruiting NCT04148053 - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting NCT01689831 - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Phase 2
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Recruiting NCT03941210 - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Recruiting NCT04494516 - Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Withdrawn NCT03265977 - A Phase II Study of H56:IC31 in Healthy Adolescents Phase 2
Recruiting NCT04236765 - Tuberculosis In Children Visiting Friends and Relatives N/A
Active, not recruiting NCT04677842 - European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Not yet recruiting NCT01798095 - Equivalence Study of Specificity of PPD Phase 2
Completed NCT02175849 - Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis N/A
Completed NCT01434758 - Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture N/A
Completed NCT04966052 - COPD Co-infection With Tuberculosis on Th17 Cell Differentiation